

Opportunity Title: FDA Research Opportunity - Bacteriophage Therapy

Opportunity Reference Code: FDA-CBER-2026-0050

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CBER-2026-0050

How to Apply *Connect with ORISE...on the GO!* Download the new ORISE GO mobile app in the [Apple App Store](#) or [Google Play Store](#) to help you stay engaged, connected, and informed during your ORISE experience and beyond!

A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 5/22/2026 3:00:00 PM Eastern Time Zone

Description *Applications will be reviewed on a rolling-basis.


FDA Office and Location: A research opportunity is currently available in the Office of Vaccine Research and Review (OVRR) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

Research Project: This project is aimed at evaluating the use of bacteriophage to treat *Staphylococcus aureus* colonization and/or disease in order to better combat multi-antibiotic-resistant bacterial pathogens. A major goal of this project is to establish and utilize animal models to investigate the potential of phage treatment against *S. aureus* to decolonize the upper respiratory tract and/or to treat *S. aureus* infections. However, other aspects will delve into aspects of the genetics of bacteriophage that are relevant to their deployment in these contexts. These include genetic mechanisms of bacterial resistance to phage and mechanisms of phage adaptation to infect different or new hosts. Work on this project will proceed on multiple fronts including mouse models of infection and phage treatment, isolation of mutant bacterial and bacteriophage strains, genetic engineering of bacterial and bacteriophage strains, isolation of bacteriophage from natural sources, next generation DNA sequence analysis.

Learning Objectives: Under the guidance of a mentor, you will conduct research in a highly collaborative environment and will be exposed to, and/or trained in, disciplines including bacteriology, bacteriophage biology, molecular biology, and bioinformatics. Methods used and areas of training





OAK RIDGE INSTITUTE
FOR SCIENCE AND EDUCATION




ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON
 Google Play

Download on the
 App Store

Opportunity Title: FDA Research Opportunity - Bacteriophage Therapy

Opportunity Reference Code: FDA-CBER-2026-0050

will include manipulation of bacteriophage, DNA sequence analysis of bacteriophage and bacteria through the use of bioinformatic tools, DNA cloning, and genetic manipulation of bacterial strains. Through attendance at research seminars, you will be exposed to a variety of other scientific disciplines and research interests. You will grow as a scientist through execution of an independent research project, group discussions, and presentations in lab meetings. You will also be able to attend varied research presentations within the FDA and NIH and have the opportunity to contribute to published research papers, with co-authorship.

Mentor: The mentor for this opportunity is Earle Stibitz (Earle.Stibitz@fda.hhs.gov). If you have questions about the nature of the research, please contact the mentor.

Anticipated Appointment Start Date: July 1, 2026. Start date is flexible and will depend on a variety of factors.

Appointment Length: The appointment will initially be for one to two years, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

Level of Participation: The appointment is full time.

Citizenship Requirements: This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the [Guidelines for Non-U.S. Citizens Details page](#) of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

FDA Ethics Requirements

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a Significantly Regulated Organization (SRO) or prohibited investment fund financial interest in any amount, or a

Opportunity Title: FDA Research Opportunity - Bacteriophage Therapy

Opportunity Reference Code: FDA-CBER-2026-0050

relationship with an SRO, except for spousal employment with an SRO, and the individual will not voluntarily divest the financial interest or terminate the relationship, then the individual is not placed at FDA. For additional requirements, see [FDA Ethics for Nonemployee Scientists](#).


FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:

- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications Applicants should have received or be currently pursuing a bachelor's or master's degree. Degree must have been received within the past five years, or is anticipated to be received by 7/1/2026.

Point of Contact [Ashley](#)

Eligibility Requirements

- **Degree:** Bachelor's Degree or Master's Degree received within the last 60 months or anticipated to be received by 7/1/2026 12:00:00 AM.
- **Discipline(s):**
 - **Life Health and Medical Sciences** ([8](#) )

Affirmation I am a U.S. citizen, or I have lived in the United States for at least 36 out of the past 60 months. (36 months do not have to be consecutive.)

I have read the FDA Ethics Requirements.